ScaleReady Grants Support Pediatric Research at Children's National Hospital

In a significant development for pediatric healthcare, ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded multiple G-Rex Grants to researchers at Children's National Hospital. This funding initiative, amounting to $375,000, aims to optimize and translate innovative cell and gene therapy projects into clinical applications, significantly benefiting children in need of advanced medical treatments.

The G-Rex Grants are specifically designed to empower leading investigators in their quest for breakthroughs in cellular therapies. Among the recipients, Dr. Patrick Hanley, Chief Director of Cell Therapy at the hospital, has received a $100,000 grant dedicated to developing a CAR-T cell manufacturing process that leverages the G-Rex platform. This approach aims to offer a more agile, cost-effective alternative compared to existing methods that are often hampered by complex and costly equipment.

Additionally, Dr. Michael Keller and Dr. Hanley have been awarded a combined $150,000 grant to innovate their Virus-Specific T cell (VST) and Tumor Antigen Associated T cell (TAAT) production methods. By transitioning to the G-Rex “M” series bioreactors, the team aims to enhance the efficiency of their manufacturing processes which, in turn, will minimize the number of manual interventions required, streamlining the production workflow.

Dr. Amy Hont, a pediatric oncologist, has also been recognized with a $75,000 grant to support her work on implementing a closed-system G-Rex manufacturing process for the novel ATTACK TAAT cell therapy. This initiative focuses on addressing various solid tumors, demonstrating the hospital's dedication to pushing the boundaries of pediatric treatment options.

Lastly, Dr. Conrad Russell Cruz, the Principal Investigator, has received a $50,000 grant aimed at optimizing CAR-modified TAAT cell manufacturing processes for the treatment of solid tumors.

In commenting on the initiative, Dr. Hanley stated, "This effort reflects the importance of working together to move promising cell and gene therapies from the lab directly to patients who need them the most. We're thankful for the support and eager to continue this vital work."

John Wilson, CEO of Wilson Wolf, expressed his pride in being able to provide funding for such talented individuals at the forefront of pediatric oncology: "Children's National has been a leader in this field for many years. It's an honor to support those pioneering advancements in pediatric cell and gene-modified therapies."

ScaleReady's G-Rex Grant Program has evolved into a major force within the industry, surpassing $40 million in product commitments to its grant recipients. The program aims to improve the development and manufacture of cell and gene therapies by providing significant financial awards of up to $300,000. Furthermore, grant winners benefit from exclusive access to a network of partners who offer essential tools and expertise in Good Manufacturing Practice (cGMP), which is crucial for maintaining quality and regulatory compliance in CGT business operations.

In conjunction with the grant announcement, ScaleReady also unveiled a new initiative called LEAN Cell Gene™, which strives to enhance the efficiency and scalability of CGT manufacturing. Through this program, all stakeholders in the cell and gene therapy sector can participate in an educational series to learn how to improve manufacturing processes, ensuring better quality and availability of drug products.

For more information about the G-Rex Grant Program or to register for the LEAN Cell Gene™ series, visit ScaleReady's website or reach out via their contact information.

About ScaleReady

ScaleReady is dedicated to improving the field of cell and gene-modified cell therapy with its innovative G-Rex manufacturing platform. Widely utilized globally, this platform supports over 800 organizations and is integral to approximately 50% of ongoing CGT clinical trials and five commercially approved CGT treatments. ScaleReady's expertise not only helps clients save time and financial resources but also accelerates their milestones toward commercialization.

About Children's National Hospital

Established in 1870, Children's National Hospital in Washington, D.C., stands among the top children's hospitals in the U.S. It is recognized for its pioneering work in pediatric medicine and innovative programs aimed at improving health outcomes for children. The establishment of the Children’s National Research & Innovation Campus further showcases its commitment to medical advancements in pediatric care.

This grant initiative not only underscores the collaborative spirit prevalent in medical research but also shines as a beacon of hope for countless children and families seeking advanced treatments for complex health challenges. Through efforts such as these, the future of pediatric healthcare continues to look brighter.